Hedge fund Tourbillion Capital Partners doesn’t like health care stock MannKind Corporation (NASDAQ:MNKD) and is betting it could tumble by as much as 90 percent, CNBC’s Lawrence Delevingne is reporting.
MannKind's Afrezza will fail due to potential customer backlash
Tourbillion thinks MannKind Corporation (NASDAQ:MNKD)’s lead diabetes treatment product, Afrezza, which recently won FDA approval, will fail due to potential customer backlash over safety concerns and higher prices than traditional insulin injection treatments.
"While Exubera has previewed what will happen with Afrezza, the market has had a way of ignoring this drug's past failures until it actually launches," an investor letter reviewed by CNBC said. "When and if this happens,...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
